This antibody is specific for IR and shows no cross-reactivity with insulin-like growth factor (IGF)-receptors. The epitope for this monoclonal antibody is conformational and is located in exon 3.
Staining of formalin-fixed, paraffin tissues requires digestion of tissue sections with pepsin at 1mg/mL in Tris-HCl, pH 2.0, for 15 min at room temperature or 10 min at 37°C. Recommended positive controls include IM-9 lymphocytes, placenta, or breast carcinoma.
Biological actions of insulin and IGF-1 are mediated by their respective cell surface receptor tyrosine kinases that regulate multiple signaling pathways through activation of a series of phosphorylation cascades. The insulin receptor. Insulin/IGF-1 binding to the extracellular domain leads to autophosphorylation of downstream target proteins. These two receptors differ in sequence in regions that confer specificity for the designated ligand as well as in certain intracellular signaling domains, resulting in significant differences in the functional consequences of activation of each receptor. Defects in IR are the cause of various insulin resistance syndromes and IGF-1R defects may cause some forms of growth retardation. Both these signaling cascades are also important for the development of cancer.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: CD220; CD220 beta; INSR; Insulin receptor; Insulin receptor subunit alpha; Insulin receptor subunit beta; IR; IR alpha; IR beta
Gene Aliases: CD220; DAF-2; HHF5; INSR; ir; ir-A
UniProt ID: (Human) P06213